Blue Industries buys gene-testing firm Genequest in all-share deal
What's the deal? Tokyo-based Blue IndustriesDealroom has a profile for this one. Try Dealroom → has acquired 100% of GenequestDealroom has a profile for this one. Try Dealroom →, making the gene-testing company a wholly owned subsidiary as of August 1, 2026. The seller is euglena. Genequest's chief executive officer, Osamu Iwata, stays on, and the company will relocate its headquarters into Blue Industries' offices.
What does each side do? Blue Industries develops "bluedrop," an at-home cancer-risk test that analyses microRNA in urine exosomes using AI to assess risk across seven cancer types. Genequest, live since 2014, offers genetic testing covering more than 360 inherited traits, from disease risk to physical characteristics.
Why now? Both companies have worked on the same problem — spotting health risks before disease sets in — using different data and technology. Combining them lets Blue Industries link inherited genetic risk to present-day cancer screening in one care pathway.
What's the endgame? The plan is a continuous health journey: genetic analysis flags inherited tendencies, then "bluedrop" evaluates current cancer risk by body part, guiding users toward the right screening and medical visits. Genequest users gain access to bluedrop, while bluedrop users can add genetic testing.
What changes for the company? Iwata continues as chief executive officer, with Shoko Takahashi, Kenji Saito, and Yuichi Hoshino remaining as directors. Blue Industries chief operating officer Kyoichi Toda joins as a director and chief executive officer Ryusuke Kuji joins as an outside director.
In their words: "By joining the Blue Industries group, we will be able to conduct research on more accurate disease prediction and prevention based on multiple types of biological data such as DNA and microRNA," said Iwata.
The signal: The deal reflects consolidation in Japan's preventive healthcare and consumer genomics space, where standalone testing services are being folded into broader risk-assessment platforms. Pairing genetic and microRNA data under one roof points to a shift toward integrated, multi-data health screening.
Read more: PR TIMES
Image credit: Centers for Disease Control and Prevention
